← All trials
NCT04706910
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 20, 2021
- Primary completion
- Dec 31, 2025
- Completion date
- Jul 31, 2026
- First posted
- Jan 13, 2021
- Last posted
- Feb 11, 2021
- Enrollment
- 800
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of AlbertaLead sponsor
- University of AlbertaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.